Advertisement
Screener

Beam Therapeutics Inc. (BEAM) Return on Tangible Equity

2.8 / 5 stars · 68/120 Roast Me

Beam Therapeutics Inc. Return Tang Equity

Return on tangible equity is the profit a company earns on the physical and financial capital its shareholders own, leaving out goodwill and other intangible assets, shown as a percentage. It is net income divided by tangible equity, which is shareholder equity minus goodwill and intangibles; the table shows both amounts. Because acquired goodwill is removed, it runs higher than ROE for companies that grew by acquisition, and it has no meaning when goodwill exceeds equity. Goodwill and intangibles are taken at the latest reported date on or before each equity date. Quarterly points divide the trailing four quarters of net income by the balance at that quarter end; annual points divide the filed fiscal-year net income by the fiscal-year-end balance.

  • Beam Therapeutics Inc. return tang equity for the quarter ending 2026-06-30 was -8.00%, a change of 29.73% year-over-year.
  • Beam Therapeutics Inc. return tang equity for the quarter ending 2026-03-31 was -5.57%, a change of 28.64% year-over-year.
  • Beam Therapeutics Inc. return tang equity for the quarter ending 2025-12-31 was -6.37%, a change of 44.99% year-over-year.
  • Beam Therapeutics Inc. return tang equity for the quarter ending 2025-09-30 was -42.81%, a change of -24.66% year-over-year.
  • Beam Therapeutics Inc. return tang equity for fiscal 2025 was -6.46%, a change of 44.90% from fiscal 2024.
  • Beam Therapeutics Inc. return tang equity for fiscal 2024 was -51.36%, a change of -37.85% from fiscal 2023.
  • Beam Therapeutics Inc. return tang equity for fiscal 2023 was -13.50%, a change of 25.91% from fiscal 2022.
  • Beam Therapeutics Inc. return tang equity for fiscal 2022 was -39.41%, a change of 5.42% from fiscal 2021.
Available history
2019-12-31 to 2026-06-30
Data captured

Historical Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2026-06-30-8.00%-$85.43M$1.07B
2026-03-31-5.57%-$64.89M$1.16B
2025-12-31-6.37%-$78.9M$1.24B
2025-09-30-42.81%-$413.55M$966M
2025-06-30-37.74%-$397.49M$1.05B
2025-03-31-34.21%-$386.4M$1.13B
2024-12-31-51.36%-$376.74M$733.55M
2024-09-30-18.15%-$143.59M$791.32M
2024-06-30-16.74%-$143.01M$854.09M
2024-03-31-14.75%-$134.74M$913.49M
2023-12-31-13.50%-$132.53M$981.33M
2023-09-30-40.27%-$313.67M$778.94M
2023-06-30-40.31%-$327.16M$811.64M
2023-03-31-41.54%-$316.33M$761.51M
2022-12-31-39.41%-$289.09M$733.47M
2022-09-30-44.15%-$315.45M$714.48M
2022-06-30-29.24%-$233.99M$800.16M
2022-03-31-28.74%-$238.29M$829.07M
2021-12-31-44.83%-$370.64M$826.74M
2021-09-30-47.01%-$401.4M$853.81M
2021-06-30-74.33%-$407.73M$548.55M
2021-03-31-86.57%-$365.69M$422.43M
2020-12-31-79.24%-$194.59M$245.56M
2020-09-30-63.47%-$126.98M$200.07M
2020-06-30-48.32%-$111.53M$230.82M
2020-03-31-36.41%-$95.17M$261.39M
2019-12-3138.95%-$78.33M-$201.1M

Annual Return Tang Equity

DateReturn Tang EquityNet income 12 monthTangible equity
2025-12-31-6.46%-$79.99M$1.24B
2024-12-31-51.36%-$376.74M$733.55M
2023-12-31-13.50%-$132.53M$981.33M
2022-12-31-39.41%-$289.09M$733.47M
2021-12-31-44.83%-$370.64M$826.74M
2020-12-31-79.24%-$194.59M$245.56M
2019-12-3138.95%-$78.33M-$201.1M

Similar stocks

Stock NameCountryMarket CapPE Ratio
Greenland Mines Ltd (GRML)United States$2.362B
BIOCRYST PHARMACEUTICALS INC (BCRX)United States$2.175B-6.63
ADMA BIOLOGICS, INC. (ADMA)United States$2.131B11.16
Kodiak Sciences Inc. (KOD)United States$2.090B-10.12
RECURSION PHARMACEUTICALS, INC. (RXRX)United States$2.080B-3.78
Vericel Corp (VCEL)United States$2.011B93.97
Denali Therapeutics Inc. (DNLI)United States$3.274B-8.04
Vir Biotechnology, Inc. (VIR)United States$1.814B-6.85
Tarsus Pharmaceuticals, Inc. (TARS)United States$3.329B-58.60
NOVAVAX INC (NVAX)United States$1.748B-6.26